About 1 000 reports

  • GASTROINTESTINAL THERAPEUTICS MARKET, GLOBAL, CLINICAL TRIAL DURATION BY
  • shows that, when gastrointestinal clinical trials are segmented by molecular target,

Global Gastrointestinal Drug Market to 2022 - Pipeline Characterized by Emerging Biologic Therapies, While TNF Inhibitors and PPIs Continue to Dominate Therapy Landscape Summary Gastrointestinal disorders are common, and a number of them have a large patient population. Across the seven major markets (the US, the UK, France,...

  • Clinical Research
  • World
  • Market Size
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited

ipage=##& xml=##& quest=##& rid=##& section=##& sequence=-##& pdf=##& dn=## [Accessed February ##, 2017].

  • Clinical Research
  • Forecast
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

GLP-## agonists have been associated with a common side effect of gastrointestinal disturbances such as nausea and vomiting, which can reduce patient compliance (Prasad-Reddy and Isaacs, 2015).

  • Clinical Research
  • World
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Eli Lilly & Co.
  • OPPORTUNITIES

TABLE ##.

  • Clinical Research
  • World
  • Forecast
  • Market Size
  • Charles River Laboratories International, Inc.
  • Porter's Five Forces Analysis

Phase ## and Phase ##, then phase ## WHICH ONE IS THE FASTEST GROWING?

  • Clinical Research
  • World
  • Forecast
  • Market Size
  • Supply
  • Porter's Five Forces Analysis

Phase ## and Phase ##, then phase ## WHICH ONE IS THE FASTEST GROWING?

  • Clinical Research
  • World
  • Forecast
  • Market Size
  • Supply

Additionally, as CF is a multi-system disease pancreatic, gastrointestinal and reproductive problems will remain even if the lung transplant is successful.

  • Clinical Research
  • World
  • Market Size
  • Alexion Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.

Grade ## hypertension (##% vs ##%), proteinuria (##% vs ##%), arterial thromboembolic events (##% vs ##%), and gastrointestinal perforation (##% vs ##%) were more commonly observed in the bevacizumab plus mIFL group than in the mIFL group.

  • Cancer
  • Clinical Research
  • World
  • Market Size
  • Merck & Co., Inc.

All treatment regimens were well tolerated, with a similar incidence of upper gastrointestinal (GI) AEs.

  • Clinical Research
  • Therapy
  • World
  • Market Size
  • Amgen Inc.

Other symptoms include retrosternal pain, weight loss, hematemesis (vomiting blood) and melena (black feces associated with gastrointestinal hemorrhage).

  • Clinical Research
  • World
  • AbbVie Inc.
  • Aduro BioTech, Inc.
  • Amgen Inc.

Minor AEs such as stomatitis, headaches, fatigue and gastrointestinal problems such as nausea and vomiting may occur when using Metolate.

  • Clinical Research
  • World
  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.

Biologics are susceptible to metabolism in the gastrointestinal tract and lack permeability, which collectively leads to poor bioavailability.

  • Clinical Research
  • World
  • AbbVie Inc.
  • Galapagos NV
  • Pfizer Inc.
  • EXOSOME TECHNOLOGIES, GLOBAL, LIST OF ALL CLINICAL TRIALS, 2006-2025 (PART 2)
  • EXOSOME TECHNOLOGIES, GLOBAL, LIST OF ALL CLINICAL TRIALS, 2006-2025 (PART 11)

Viral Vectors for Gene Therapy. ## (##), ##-##.

  • Clinical Research
  • CAP-1002 group
  • Capricor Therapeutics, Inc.
  • Mirna Therapeutics, Inc.
  • ReNeuron Group plc

The ACURATE family of valve products is one of two valve systems in the Boston Scientific structural heart portfolio.

  • Clinical Research
  • Prosthesis
  • United States
  • Edwards Lifesciences Corporation
  • Valtech Cardio, Ltd.

Gastrointestinal Cancer Research; ##(##): ##-## Mayo Clinic (2014).

  • Clinical Research
  • World
  • AbbVie Inc.
  • Janssen Biotech, Inc.
  • Johnson & Johnson

DURING CHILDHOOD, ASTHMA IS MORE COMMON IN MALES, WITH A MALE-TO-FEMALE RATIO OF ##:## UP TO PUBERTY, WHEN IT CHANGES TO ##:##.

  • Clinical Research
  • World
  • Market Size
  • Astellas Pharma Inc.
  • AstraZeneca PLC

Heparin is given intravenously due to poor gastrointestinal tract absorbability.

  • Clinical Research
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

As such, non-selective COX inhibitors typically produce COX-## inhibitory gastrointestinal (GI) side effects, including gastric ulceration, bleeding and perforation.

  • Clinical Research
  • World
  • Market Size
  • Allergan plc
  • Amgen Inc.

Indian Journal of Ophthalmology; ##(##): ## Pfizer.

  • Clinical Research
  • World
  • Forecast
  • Market Size
  • Clearside Biomedical, Inc.

Report Title Published Date ##.

  • Clinical Research
  • North America
  • United States
  • World
  • Horizon Discovery
  • Ph ase I
  • Pharmaceutical Industry, Clinical Trial Duration in Phase I by Therapy Area, 2006-

Health Affairs; ##(##): ##-## Vernon J, et al. (2010).

  • Clinical Research
  • Pharmaceutical
  • Therapy
  • United States
  • Market Size

When gastrointestinal AEs were reported their intensity was much lower than with oxycodone.

  • Clinical Research
  • World
  • Amgen Inc.
  • Daiichi Sankyo Company
  • Eli Lilly & Co.

GLP-## IS AN INCRETIN HORMONE THAT IS RELEASED FROM CELLS IN THE GASTROINTESTINAL TRACT INTO THE CIRCULATION IN RESPONSE TO INGESTED NUTRIENTS FROM FOOD.

  • Clinical Research
  • Southeast Asia
  • Market Size
  • Novo Nordisk Group
  • Sanofi S.A.
  • LINZESS: CURRENT STATUS OF DEVELOPMENT
  • 8.3.7. CLINICAL STUDIES

DIGESTIVE AND GASTROINTESTINAL DISORDERS DIGESTIVE AND GASTROINTESTINAL DISORDERS ARE ONE OF THERAPEUTIC AREAS THAT ARE TARGETED BY SEVERAL ORAL PEPTIDE / PROTEIN THERAPEUTICS THAT ARE EITHER MARKETED OR UNDER DEVELOPMENT.

  • Clinical Research
  • North America
  • United States
  • Ironwood Pharmaceuticals, Inc.
  • Novo Nordisk Group
  • Clinical Trials by E7 Countries: Proportion of Functional (Non Ulcer) Dyspepsia to Gastrointestinal Clinical Trials
  • Clinical Trials by G7 Countries: Proportion of Functional (Non Ulcer) Dyspepsia to Gastrointestinal Clinical Trials

Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H1, 2015" provides data on the Functional (Non Ulcer) Dyspepsia clinical trial scenario. This report provides elemental information and data...

  • Clinical Research
  • World
  • Actavis plc
  • Astellas Pharma Inc.
  • Zeria Pharmaceutical Co., Ltd.

Overall, there was one serious adverse event of moderate gastrointestinal infection that was determined by the investigator not to be drugrelated.

  • Clinical Research
  • World
  • Forecast
  • Market Size
  • Pharming Group NV

IMRT HAS HELPED TO DECREASE THE OCCURRENCE OF GASTROINTESTINAL (GI) TOXICITIES USUALLY ASSOCIATED WITH EBRT.

  • Clinical Research
  • Hormone
  • Prostate Cancer
  • Therapy
  • PROVENGE group

The Pharma Innovation; ##(##): ##-## Bresnick GH (1983).

  • Clinical Research
  • World
  • Adverum Biotechnologies, Inc.
  • Alcon, Inc.
  • Allergan plc

Neurologic side effects such as headaches and visual abnormalities, as well as gastrointestinal disorders have also been reported.

  • Clinical Research
  • World
  • Market Size
  • AbbVie Inc.
  • Janssen Biotech, Inc.

This method avoids the gastrointestinal tract and leads to more rapid effects, compared to orally administered levodopa.

  • Clinical Research
  • World
  • Biogen Idec Inc.
  • Novartis AG
  • Roche Group